Talphera Inc (TLPH) — Titan Protect Analysis

TLPH

Talphera Inc

Healthcare · ·

$0.78

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$41M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.14

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-118.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$3.25

+317% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 2 analysts covering this stock

About Talphera Inc

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acu

https://talphera.com

Country: United States Employees: 12 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.319

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0940

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.160

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-10.6%

Historical annualised return based on price data

Max Drawdown

-66.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$1.57

50% below the year high

52W Low

$0.38

105% above the year low

Avg Volume

160,950

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.28

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

35.17

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,451,600.0%

Profit from core operations before interest and tax

Free Cash Flow

$-5,777,500

Negative — the business is spending more than it generates

Revenue (TTM)

$1,000

Total revenue over the last 12 months

Net Income

$-14,253,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$3.50

Target Median

$3.25

Target Low

$3.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go